|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
WO2007091066A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Ucl Business Plc |
Applications of non-integrating lentiviral vectors
|
|
AU2008285224B2
(en)
*
|
2007-08-03 |
2015-01-22 |
Centre National De La Recherche Scientifique (Cnrs) |
Lentiviral gene transfer vectors and their medicinal applications
|
|
PL2020444T3
(pl)
*
|
2007-08-03 |
2017-10-31 |
Pasteur Institut |
Wadliwe nieintegrujące lentiwirusowe wektory przenoszące dla szczepionek
|
|
AU2013203416B2
(en)
*
|
2007-08-03 |
2016-10-13 |
Centre National De La Recherche Scientifique (Cnrs) |
Lentiviral gene transfer vectors and their medicinal applications
|
|
AU2008317354B2
(en)
|
2007-10-25 |
2014-04-10 |
Ospedale San Raffaele S.R.L. |
Methods and compositions for targeted integration
|
|
CA2719938A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Virxsys Corporation |
Lentivirus-based immunogenic vectors
|
|
WO2009131706A1
(en)
*
|
2008-04-26 |
2009-10-29 |
Yung-Nien Chang |
Site-specific-integration lentiviral vectors
|
|
US20120135034A1
(en)
*
|
2009-03-13 |
2012-05-31 |
Boro Dropulic |
Non-Integrating Retroviral Vector Vaccines
|
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
AU2011215557B2
(en)
|
2010-02-09 |
2016-03-10 |
Sangamo Therapeutics, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
DK2385107T3
(en)
|
2010-05-03 |
2016-12-12 |
Pasteur Institut |
Lentiviral vector-based immunological compounds against malaria
|
|
WO2012152912A1
(en)
|
2011-05-12 |
2012-11-15 |
Newvectys |
Genetically modified pig as a cancer prone model
|
|
ES2651922T3
(es)
|
2011-11-08 |
2018-01-30 |
Institut Pasteur |
Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
|
|
GB201202516D0
(en)
|
2012-02-13 |
2012-03-28 |
Ucl Business Plc |
Materials and methods relating to packaging cell lines
|
|
US9713635B2
(en)
|
2012-03-30 |
2017-07-25 |
Immune Design Corp. |
Materials and methods for producing improved lentiviral vector particles
|
|
NZ700340A
(en)
|
2012-03-30 |
2017-02-24 |
Immune Design Corp |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
EP3620524A1
(en)
*
|
2013-06-17 |
2020-03-11 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
CN105793425B
(zh)
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
CN106062197A
(zh)
|
2013-06-17 |
2016-10-26 |
布罗德研究所有限公司 |
用于序列操纵的串联指导系统、方法和组合物的递送、工程化和优化
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
US20160230190A1
(en)
*
|
2013-09-17 |
2016-08-11 |
Inserm ( Institut National De La Sante Et De La Re Cherche Medicale) |
Lentiviral Vectors Having a Mutated Integrase Protein and uses Thereof
|
|
EP2878667A1
(en)
|
2013-11-29 |
2015-06-03 |
Institut Pasteur |
TAL effector means useful for partial or full deletion of DNA tandem repeats
|
|
EP3080257A1
(en)
|
2013-12-12 |
2016-10-19 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
MX374530B
(es)
|
2013-12-12 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de los sistemas y composiciones crispr-cas para actuar sobre hbv y trastornos y enfermedades virales.
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
CN118813621A
(zh)
|
2013-12-12 |
2024-10-22 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
WO2015164759A2
(en)
|
2014-04-25 |
2015-10-29 |
Bluebird Bio, Inc. |
Mnd promoter chimeric antigen receptors
|
|
AU2015249376C1
(en)
|
2014-04-25 |
2019-10-31 |
2Seventy Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
SG11201610170SA
(en)
|
2014-06-06 |
2017-01-27 |
Bluebird Bio Inc |
Improved t cell compositions
|
|
CA2956002C
(en)
|
2014-07-24 |
2023-06-27 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
EP3031923A1
(en)
|
2014-12-11 |
2016-06-15 |
Institut Pasteur |
Lentiviral vector-based japanese encephalitis immunogenic composition
|
|
AU2015360845B2
(en)
|
2014-12-12 |
2020-11-26 |
2Seventy Bio, Inc. |
BCMA chimeric antigen receptors
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
WO2016205613A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
WO2017053707A1
(en)
|
2015-09-23 |
2017-03-30 |
Sensoriant, Inc. |
Method and system for using device states and user preferences to create user-friendly environments
|
|
WO2017060662A1
(en)
*
|
2015-10-07 |
2017-04-13 |
The Secretary Of State For Health |
Method for providing a control for use in a screen for pathogenic virus
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
CN109311963A
(zh)
|
2016-04-14 |
2019-02-05 |
蓝鸟生物公司 |
救助嵌合抗原受体系统
|
|
WO2017214938A1
(zh)
*
|
2016-06-16 |
2017-12-21 |
毛侃琅 |
特异促进 bace1 基因高表达的慢病毒表达载体及应用
|
|
CA3034094A1
(en)
|
2016-08-16 |
2018-02-22 |
Bluebird Bio, Inc. |
Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
|
|
EP3504335A4
(en)
|
2016-08-23 |
2020-04-15 |
Bluebird Bio, Inc. |
HOMING TIM3 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
CA3035455A1
(en)
|
2016-09-08 |
2018-03-15 |
Bluebird Bio, Inc. |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
|
AU2017346683B2
(en)
|
2016-10-17 |
2024-04-18 |
Regeneron Pharmaceuticals, Inc. |
TGFβR2 endonuclease variants, compositions, and methods of use
|
|
JP7093346B2
(ja)
|
2016-11-04 |
2022-06-29 |
２セブンティ バイオ インコーポレイテッド |
抗ｂｃｍａ ｃａｒ ｔ細胞組成物
|
|
JP7263235B2
(ja)
|
2016-11-17 |
2023-04-24 |
２セブンティ バイオ インコーポレイテッド |
ＴＧＦβシグナルコンバーター
|
|
MA47847A
(fr)
*
|
2016-12-06 |
2020-01-29 |
Bluebird Bio Inc |
Thérapie génique pour traiter la mucopolysaccharidose de type i
|
|
MX2019006551A
(es)
*
|
2016-12-06 |
2019-10-15 |
Bluebird Bio Inc |
Terapia génica para mucopolisacaridosis de tipo ii.
|
|
EP3357504A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
|
|
EP3357506A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
|
|
JP7236398B2
(ja)
|
2017-02-15 |
2023-03-09 |
２セブンティ バイオ インコーポレイテッド |
ドナー修復鋳型多重ゲノム編集
|
|
JP7191042B2
(ja)
|
2017-05-25 |
2022-12-16 |
２セブンティ バイオ インコーポレイテッド |
Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法
|
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
FI3633040T3
(fi)
|
2017-12-22 |
2023-08-03 |
Oxford Biomedica Ltd |
Retrovirusvektori
|
|
DE102018010282A1
(de)
|
2018-01-17 |
2019-07-18 |
Immatics US, Inc. |
Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren
|
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|
|
AU2019287720B2
(en)
|
2018-06-14 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
CD79A chimeric antigen receptors
|
|
EP3820515A1
(en)
|
2018-07-11 |
2021-05-19 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
KR20210102870A
(ko)
|
2018-08-30 |
2021-08-20 |
테나야 테라퓨틱스, 인코포레이티드 |
미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
US12404500B2
(en)
|
2018-12-10 |
2025-09-02 |
Novo Nordisk A/S |
Homing endonuclease variants
|
|
CA3123084A1
(en)
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
JP7630176B2
(ja)
|
2019-04-01 |
2025-02-17 |
テナヤ セラピューティクス， インコーポレイテッド |
操作されたカプシドを有するアデノ随伴ウイルス
|
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
EP3770264A1
(en)
|
2019-07-22 |
2021-01-27 |
Genethon |
Precise integration using nuclease targeted idlv
|
|
WO2021051390A1
(zh)
|
2019-09-20 |
2021-03-25 |
上海吉倍生物技术有限公司 |
靶向bcma的抗体及嵌合抗原受体
|
|
IL292566A
(en)
|
2019-11-05 |
2022-06-01 |
Celgene Corp |
Uses of anti-bcma chimeric antigen receptors
|
|
JP7759318B2
(ja)
|
2019-11-12 |
2025-10-23 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
産生系
|
|
US20240052366A1
(en)
|
2020-02-13 |
2024-02-15 |
Oxford Biomedica (Uk) Limited |
Production of Lentiviral Vectors
|
|
JP2023516493A
(ja)
|
2020-03-13 |
2023-04-19 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
レンチウイルスベクター
|
|
WO2021212279A1
(zh)
*
|
2020-04-20 |
2021-10-28 |
广东东阳光药业有限公司 |
慢病毒的滴度提高型转移质粒
|
|
CN111534533B
(zh)
*
|
2020-04-27 |
2022-04-19 |
北京化工大学 |
一种t7rna聚合酶和t7启动子的表达系统及使用其在真核生物中表达蛋白质的方法
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
EP3984548A1
(en)
|
2020-10-16 |
2022-04-20 |
Institut Pasteur |
Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
|
|
US20230398149A1
(en)
|
2020-11-04 |
2023-12-14 |
Celgene Corporation |
Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
KR20230117383A
(ko)
|
2020-12-04 |
2023-08-08 |
셀진 코포레이션 |
염증-관련 가용성 인자의 억제제와 조합된 키메라 항원수용체 (car) t-세포 요법의 용도
|
|
BR112023018329A2
(pt)
|
2021-03-12 |
2023-10-10 |
Pasteur Institut |
Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral
|
|
CA3214280A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
T cell therapy in patients who have had prior stem cell transplant
|
|
EP4370541A1
(en)
|
2021-07-14 |
2024-05-22 |
2seventy bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
CN114181972A
(zh)
*
|
2021-11-23 |
2022-03-15 |
上海本导基因技术有限公司 |
适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
|
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
|
WO2023196996A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
|
JP2025518626A
(ja)
|
2022-04-13 |
2025-06-18 |
ウニベルシタット アウトノマ デ バルセロナ |
クロトータンパク質を発現する遺伝子療法を介した神経筋疾患の治療
|
|
KR20250008774A
(ko)
|
2022-05-11 |
2025-01-15 |
셀진 코포레이션 |
T 세포 요법 및 그의 생산과 관련된 방법 및 용도
|
|
WO2023230512A1
(en)
|
2022-05-26 |
2023-11-30 |
2Seventy Bio, Inc. |
Compositions for maintaining lentiviral vector and uses thereof
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
TW202423456A
(zh)
|
2022-10-21 |
2024-06-16 |
法商賽拉福柯蒂斯公司 |
表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
WO2024200573A1
(en)
|
2023-03-27 |
2024-10-03 |
LAVA Therapeutics N.V. |
Nectin-4 binding agents and methods of use
|
|
WO2025012118A2
(en)
|
2023-07-07 |
2025-01-16 |
LAVA Therapeutics N.V. |
5t4 binding agents and methods of use
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025153530A1
(en)
|
2024-01-16 |
2025-07-24 |
Novo Nordisk A/S |
Albumin-targeted endonucleases, compositions, and methods of use
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|